BIOGEN IDEC - “Refuse to File Letter” to Lemtrada = Modest Positive for BIIB
Delay in the launch of Sanofi’s Lemtrada (alemtuzumab, anti-CD52 mAbs, RRMS) by at least 6 months or more will be perceived as a modest positive for Biogen Idec (BIIB) which should continue to dominate the MS space. BIIB has been one of our top picks for 2012 with its promise of growth on the strength of its marketed products and pipeline. It is poised to enrich its revenue stream and MS franchise in 2012/13 with the launch of oral BG-12. Clinical news flow from… for more detail, please read our report released on 27th August, 2012 on BIIB titled, “Refuse to File Letter" to Lemtrada = Modest Positive for BIIB”.
